HBA 2020 Woman of the Year Announced
The Healthcare Businesswomen’s Association (HBA) last night announced the 2020 Woman of the Year during a reception at the J.P. Morgan Healthcare Conference.
Dr. Sandra Horning, former chief medical officer and head of global product development, Genentech and Roche, will be recognized at the HBA’s 31st annual Woman of the Year event on 29 April in New York City.
The HBA Woman of the Year award honors a female senior executive whose accomplishments have resulted in significant contributions to the healthcare industry.
During her tenure at Genentech and Roche, Dr. Horning helped to bring 15 new medicines to patients in neuroscience, ophthalmology, immunology, infectious disease and hematology/oncology. Driving for early access to life-saving medicines, she collaborated with the FDA and others in breakthrough therapy designation and early endpoints for regulatory approval. As a distinguished clinical investigator, she has been recognized as a global leader in the field of hematology/oncology and a respected clinician and scientist at the cutting edge of cancer research.
Beyond her contributions to medicine, Dr. Horning has been a passionate advocate for women in leadership both in the academy and in the office. During her tenure, gender parity increased across product development at Genentech and Roche at the senior leadership level. Currently, all five global product development sites at Genentech and Roche are led by women.
Look out for Pharm Exec’s cover profile of Dr. Sandra Horning in the April 2020 issue.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
